{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:39:37Z","timestamp":1787315977880,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,17]]},"DOI":"10.7759\/cureus.18040","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T07:05:16Z","timestamp":1631862316000},"source":"Crossref","is-referenced-by-count":7,"title":["Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis"],"prefix":"10.7759","author":[{"given":"Sawyer J","family":"Bawek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McGovern-Poore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Khoncarly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravish","family":"Narvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer J","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al.. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015, 373:123-35. 10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone DP","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, et al.. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017, 376:2415-26. 10.1056\/NEJMoa1613493","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017, 377:1345-56. 10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi NA","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, et al.. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015, 16:257-65. 10.1016\/S1470-2045(15)70054-9","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Valenti-Azcarate R","year":"2020","unstructured":"Valenti-Azcarate R, Esparragosa Vazquez I, Toledano Illan C, Idoate Gastearena MA, G\u00e1llego P\u00e9rez-Larraya J. Nivolumab and ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation. Neuromuscul Disord. 2020, 30:67-9. 10.1016\/j.nmd.2019.10.006","journal-title":"Neuromuscul Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki S","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al.. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-34. 10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14946","article-title":"Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies","volume":"50","author":"Fazal M","year":"2020","unstructured":"Fazal M, Prentice DA, Kho LK, Fysh E. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies. Intern Med J. 2020, 50:1003-6. 10.1111\/imj.14946","journal-title":"Intern Med J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel M","year":"2019","unstructured":"Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Reports Immunol. 2019, 2019:2539493. 10.1155\/2019\/2539493","journal-title":"Case Reports Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis Concomitant with myasthenia gravis","volume":"10","author":"Fukasawa Y","year":"2017","unstructured":"Fukasawa Y, Sasaki K, Natsume M, et al.. Nivolumab-induced myocarditis Concomitant with myasthenia gravis. Case Rep Oncol. 2017, 10:809-12. 10.1159\/000479958","journal-title":"Case Rep Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/70045-nivolumab-induced-myasthenia-gravis-concomitant-with-myocarditis-myositis-and-hepatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:31:51Z","timestamp":1707489111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/70045-nivolumab-induced-myasthenia-gravis-concomitant-with-myocarditis-myositis-and-hepatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.18040","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,17]]}}}